DEVELOPMENT OF TRANSLATIONAL MEDICINE University of Medicine & Pharmacy (UMP)

Ho Chi Minh City - Vietnam

Members of the Biomedicine Program at UMP

2

Thuy Thanh Thi Do, MD PhD - Vice Director

Bao Chi Bui, PhD - Faculty

Vu Anh Hoang, MD PhD - Vice Director

Son Tan Vo, MD PhD - Director

Thai Duc Nguyen, PhD - Advisor/International Relation

Minh Duc Do, MD PhD - Faculty

Tuan Thanh Huynh, MD PhD - Faculty

UNIVERSITY MEDICAL CENTER

UNIVERSITY MEDICAL CENTER

Address: 215 Hong Bang St., Dist.5, Ho Chi Minh City, Viet Nam Tel: (84-8) 3855 4269 Email: bvdh@umc.edu.vn Website: www.bvdaihoc.com.vn

University of Medicine & Pharmacy (UMP)

Prof. Nguyen, D. HoiFounder & DeanUMP Hospital

Prof. Tran, Diep TuanPresident, UMP

As a leading institute in medical education of Vietnam, the promotion of scientific research activities has always been an active and pivotal part of our mission.

UMP is now taking the new challenge in developing modern biomedical research to align our scientific programs with the international medical community, and importantly, to harness the advancements of biological sciences for medical services, via translational research, for unmet medical illnesses of the Vietnamese patients.

Philosophy & DirectionThe TRANSLATIONAL MEDICINE of UMP aspires to create: - Biomedical doctors and life science researchers

of Vietnam to innovate the basic and clinical research in and their applications on health care

- A rich biotech ecosystem, besides conventional trainings, at all stages and agendas of the school in response to the demand for innovation

- A necessary responsible social agenda aiming for needs-driven innovation serving the general population of Vietnam

STEPS FOR TRANSLATIONAL RESEARCH & MEDICAL PRACTICE AT UMP

1) Create Biomedical Program/UMP as an academic home for Translational Research associates with clinical studies at hospitals of HCM City and other parts of Vietnam.

2) Identify innovative and beneficial research projects and facilitate bench-to-bedside translation (e.g. diagnostics, therapies).

3) Facilitate clinical investigators at hospitals to benefit from Translational Research at UMP and collaborators (e.g. efficient clinical studies).

4) Translate health benefits to the public via engagement of the hospitals and its affiliates.

BioMed Clinical investigators Hospitals Public

(Dean Ken-Ichi Arai -JAPAN)

Teaching: Biomedicine

Collaboration: - Partnership with leading institutes of VN & international

Conference: - Importing the world knowledge - Promoting progresses of Vietnam

Advisory: - Connecting to the international community - Assisting development in VN

R&D: - Building biotech platforms for innovation toward advancement

Industry Relation: - Building Biotech group for commercialization

Building the Biomedical Program at UMP - Ho Chi Minh City

TRANSLATIONAL MEDICINE

SIGNIFICANCE (UMP Biomedical Program)

- Training grassroots of biomedical scientists/physicians to promote biomedicine for Vietnam health care - Improving efficacy of health care via implementation of biotechnologies in the R&D on unmet medical issues affecting the Vietnamese population - Promoting high value biologics via developing bio-pharmaceutical sectors of Vietnam - Achieving the ultimate goal of making UMP a modern biomedical research center of Vietnam

RESEARCH DIRECTION

+ cytokines

DC CANCER THERAPY

Viet Quoc Pham, Sinh Truong Nguyen, Phuc Van Pham: Production of functional dendritic cells from mouse bone marrow. Biomedical Research and Therapy. 09/2014; 1(4).

Pham Van Phuc, Chi Jee Hou, Nguyen Thi Minh Nguyet, Duong Thanh Thuy, Le Van Dong, Truong Dinh Kiet, Phan Kim Ngoc: Effects of breast cancer stem cell extract primed dendritic cell transplantation on breast cancer tumor murine models. Annual Review & Research in Biology. 01/2011; 1:1-13.

20

Khanh Hong-Thien Bui, Triet Dinh Duong, Nhan Thanh Nguyen, Thanh Duc Nguyen, Vien Tuong Le, Viet Thanh Mai, Nhan Lu-Chinh Phan, Dung Minh Le, Ngoc Kim Phan, Phuc Van Pham: Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. Biomedical Research and Therapy. 02/2014; 1(1):2-8.

Phuc Van Pham, Ngoc Bich Vu, Thuy Thanh Duong, Tam Thanh Nguyen, Nhung Hai Truong, Nhan Lu Chinh Phan, Tue Gia Vuong, Viet Quoc Pham, Hoang Minh Nguyen, Kha The Nguyen, Nhung Thi Nguyen, Khue Gia Nguyen, Lam Tan Khat, Dong Van Le, Kiet Dinh Truong, Ngoc Kim Phan: Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment.. OncoTargets and Therapy 01/2012; 5:77-84.

Monoclonal Antibodies (mAb)

Procedures for mAb Cloning

Therapeutic mAb

A

B

C

Inoculation

Hybridoma

Cloning L-H

D Humanization

1st2nd

3rd

R&D PROJECTS Novel HBV Vaccine: The 3 rd Generation

HBV Vaccines & VLP (virus like particle) Technologies 1 st generation: HBV surface antigens from the serum of hepatitis patients, Australia; approved in 1980. 2 nd generation: Recombinant VLP vaccine from yeast using S antigen (i.e. HBsAg) by Chiron, USA; approved in 1986 . 3 rd generation: Recombinant VLP vaccine from CHO using multi complex antigens of S, PreS1 and PreS2 (Sci-B-Vac by SciGen), Israel; approved in 2013

infectious

not infectious

VLP Vaccines vs. Traditional Vaccines 1 - Very safe due to lack of the viral nuclear DNA/RNA genes, and eggs are not used & could be applied universally for other viruses. 2 - VLP vaccines elicit stronger and longer immune responses than conventional vaccines. 3 - Induce neutralizing antibody responses to both primary and conformational epitopes 4 - The VLP vaccines are cell-based using E. coli, insect cells or fungi with much higher yield from 10-50 folds. 5 - Economical production, much shorter time for quick response to urgent epidemics (about 2 months compared to the 6 mons-1year).

PreS1

PreS2 S

VLP Technologies

Virus

Cloning & expression PreS1, PreS2 & S genes

HBV genome Virion

* Novel biomarkers for early detection of liver cancer

Glycan-3, GP73, HBV receptor & others

*Improved Methodologies (Nano particles)

Biomarkers for early detection of liver cancer

ACTIVITIES

Expanding Development

Dendritic Cell (DC) research for cancer therapies

Dr. Phuc Pham, Stem Cell Research Program - HCMUS

GeneWorld Co., SHTP

IVAC products

Biosimilar mAb – Nanogen, SHTP

Conferences & Meetings on Biotechnology in Vietnam

MMU Hanoi SHTP

The 1st GIC-VN 2013: A drive for Biomedical Innovation - Vietnam

The 1st Biomed Conference (UMPH - 2001)

Biotechnology R&D Vietnam - Hanoi NUS Research Laboratories

    Animal Cell Biotechnology (ACB)    Genetic Engineering (GEL)

    Animal Gene Technology (AGT)    Genetics of Microorganisms (MGL)

         Immunology (IML)     Bio-active Compounds from Microorganisms (BCM)    Molecular Microbiology (MMB)

    Biology of Reproduction Cells (BRC)    Petroleum Microbiology (PML)

    Algae Biotechnology (ABT)    Photobiology (PHB)

    Embryo Technology (ETL)    Plant Biochemistry (PBC)

    Enzyme Biotechnology (EBL)    Plant Cell Biotechnology (PCB)

    Enzymology (EZL)    Plant Cell Genetics (PCG)

    Environmental Biotechnology (EBT)    Protein Biochemistry (PBL) Stem Cell Research (SCL)

    Fermentation Technology (FTL)    Soil Microbiology (SML)         

Summary of Vietnam Biotech Progresses

1994 2014

PCR - Mass-Spec

- Protein/mAb

- Cell/Gene Therapy

- Need significant improvements for international standard, efficiency

- Require sustained government support

- Participation of advanced institutes abroad

- Open for partnerships and investments

The world incubator of biomedical education & development

Prof. Herbert Boyer Inventor of Biotechnology Founder, Genentech Inc.

The Creation of Biotechnology (1973)

University of Califonria, San Francisco (UCSF)

UCSF

SBI Biotech- Tokyo

UCSF

Connecting the Dots: from the Glaucoma Gene to Vietnam Biotech

Nature 1997

The 2nd Gene & Immunotherapy Conference - Vietnam (2015)

Together, we can make the difference!

Thank you